The addition of 1 year of the PARP inhibitor olaparib after completion of standard neoadjuvant or adjuvant chemotherapy, surgery and any radiation therapy needed, significantly improved invasive disease-free (IDFS) and distant disease-free survival (DDFS) in patients with BRCA1/2 germline mutations and high-risk early-stage breast cancer that is negative for human epidermal growth factor receptor 2-(HER2), according to new research to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 3, 2021
June 3, 2021
Additional chemotherapy given after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and is associated with additional side effects, according to results of a phase III international trial.
June 3, 2021
The investigational therapy 177Lu-PSMA-617 significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) when added to standard of care treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with standard of care alone, according to new research.
May 27, 2021
ALEXANDRIA, Va. - Conquer Cancer, the ASCO Foundation, is pleased to announce the recipients of its awards supporting researchers with projects spanning across many areas in cancer care, including immunotherapy, precision medicine, breast cancer, and palliative care. The awards will be given in conjunction with the 2021 ASCO Annual Meeting.
May 26, 2021
Twenty-seven studies exploring a wide range of topics across many cancer disease sites will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place online June 4-8.
May 25, 2021
The Association for Clinical Oncology (ASCO) congratulates Chiquita Brooks-LaSure on her confirmation as Administrator of the Centers for Medicare & Medicaid Services (CMS). Administrator Brooks-LaSure is now in a key position to lead CMS during the agency’s continued response to the COVID-19 pandemic and the evolving implementation of the Affordable Care Act (ACA) under the new Administration.
May 19, 2021
In a review of the incidence and trends of the Human Papillomavirus- (HPV-) related cancers, a new study found that over the last 17 years, the incidence of cervical cancer has decreased annually by 1%, while the incidence of other HPV-related cancers continues to increase.
May 19, 2021
Younger African American men undergoing frequent prostate cancer screening appear to have both a lower risk of metastasis at the time of prostate cancer diagnosis and of fatal disease, according to data from an observational study to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 19, 2021
Treatment with the immunotherapy atezolizumab extended disease-free survival (DFS) in patients with resected, early-stage non-small cell lung cancer (NSCLC), particularly those positive for the immune checkpoint protein PD-L1, according to new research to be presented at the 2021 ASCO Annual Meeting. The findings open the door to delaying recurrence even longer for patients with early-stage disease.
May 19, 2021
Survival for patients with newly diagnosed cancer is longer in states with higher Medicaid income eligibility limits.
May 19, 2021
When compared to anti-PD-1 monotherapy, two immunotherapy agents blocking different checkpoints extended time to disease progression for patients with previously untreated, unresectable, or metastatic melanoma, new research found.
May 11, 2021
A new special series in JCO Oncology Practice, a journal of the American Society of Clinical Oncology (ASCO), explores the causes of disparities in cancer care and outcomes for Black people in the United States and examines potential solutions to begin to achieve health equity for this population.
May 3, 2021
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced plans to test a research site assessment tool and implicit bias training program, both of which are designed to address one of the barriers to clinical trial participation: trials not routinely being offered by clinicians to eligible patients.
April 28, 2021
Advances in the treatment of prostate, breast, lung, and renal cancers as well as screening, prevention, access to care, immunotherapy, and precision medicine will be highlighted in the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting’s official Press Program.
April 22, 2021
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of the American Society of Clinical Oncology’s (ASCO) Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation.
Pages |